SWITZERLAND – Novartis has signed an agreement to manufacture Carisma Therapeutics’ HER2-targeted CAR-M cell therapy, which is currently being studied for the treatment of solid tumors. Carisma will begin transferring…
Read MoreNovartis signs deal with Carisma Therapeutics for contract manufacturing business
